CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer
Slideset - Phase III study of adjuvant capecitabine in patients with HER2-negative breast cancer and pathologic residual disease following standard anthracycline/taxane neoadjuvant chemotherapy.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Xeloda